Skip to content

To keep going please Log in.

Sign Up Sign In
or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Sign up.

Sign Up Sign In
or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

OVID Ovid Therapeutics Inc. Common Stock
$0.31 -2.61% -0.01
Notify me if price changes either direction
Interactive Brokers Logotype

Buy OVID stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 22.7M
Enterprise value -5910509
Trailing PE -0.84189189189189
Forward PE -0.8169231
PEG Ratio -0.8169231
Enterprise to EBITDA 0.112
Enterprise to revenue -10.786
Price to book MRQ 0.3820144
Price to sales TTM 41.342133

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-03-31
Revenue (TTM) 548.0K
EBITDA -52900000
Diluted EPS TTM -0.34
Total Cash (MRQ) 43.0M
Current ratio (MRQ) 4.934
Operating Cash Flow (TTM) -49550000

OVID trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
75% sells
25% buys
Upgrade Today
In the last 0 months

Recent OVID News

Trade, Swap & Stake Crypto on Uphold

Buy, sell, and swap crypto. Stake crypto, earn rewards and securely manage 300+ assets—all in one trusted platform. Terms apply. Capital at risk.

Get Started

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.